Warfarin
Appearance
Unchecked
|
| |
| Systematic (IUPAC) name | |
|---|---|
| (RS)-4-Hydroxy-3-(3-oxo-1-phenylbutyl)- 2H-chromen-2-one | |
| Clinical data | |
| Trade names | Coumadin, Jantoven, Marevan |
| Licence data | US FDA:link |
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral or intravenous |
| Pharmacokinetic data | |
| Bioavailability | 79-100% (Oral)[1] |
| Protein binding | 99%[2] |
| Metabolism | Hepatic: CYP2C9, 2C19, 2C8, 2C18, 1A2 and 3A4[2] |
| Half-life | 20-60 hours (mean: 40 hours)[2] |
| Excretion | Renal (92%)[2] |
| Identifiers | |
| CAS number | 81-81-2Template:CasciteI |
| ATC code | B01AA03 |
| PubChem | CID 54678486 |
| DrugBank | DB00682 |
| ChemSpider | 10442445Template:Chemspidercite |
| UNII | 5Q7ZVV76EITemplate:Fdacite |
| KEGG | D08682Template:Keggcite |
| ChEBI | CHEBI:10033 Template:Tick |
| ChEMBL | CHEMBL1464 Template:Tick |
| Chemical data | |
| Formula | C19H16O4 |
| Mol. mass | 308.33 g/mol |
| |
| |
| | |
foobar
- ↑ Holford, NH: [http://link.springer.com/article/10.2165%2F00003088-198611060-00005 Clinical Pharmacokinetics and Pharmacodynamics of Warfarin Understanding the Dose-Effect Relationship.] In: Springer International Publishing (Hrsg.): Clinical Pharamacokinetics. 11, Nr. 6, December 1986, S. 483-504. Script error: No such module "Vorlage:Handle".. PMID 3542339.
- 1 2 3 4 "PRODUCT INFORMATION COUMADIN" (PDF). TGA eBusiness Services. Aspen Pharma Pty Ltd. 19 January 2010. Retrieved 11 December 2013.